Aligos Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $1,269 | $1,061 | $986 | $2,681 |
Gross Profit | 1,269 | 451 | 312 | 1,906 |
EBITDA | -19,464 | -26,414 | -21,372 | -27,147 |
EBIT | -20,131 | -27,024 | -22,046 | -27,922 |
Net Income | -19,259 | 5,061 | -34,863 | -27,892 |
Net Change In Cash | 1,269 | 1,061 | 986 | 2,681 |
Free Cash Flow | -20,127 | -19,500 | -22,815 | -22,665 |
Cash | 35,331 | 45,148 | 24,367 | 135,774 |
Basic Shares | 6,272 | 3,092 | 3,092 | 12,672 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $15,529 | $13,907 | $4,359 | $-10,548 |
Gross Profit | 12,460 | 13,907 | 4,359 | -10,548 |
EBITDA | -83,815 | -93,905 | -124,543 | -94,509 |
EBIT | -86,884 | -97,580 | -128,321 | -97,834 |
Net Income | -87,679 | -96,046 | -128,332 | -108,543 |
Net Change In Cash | 15,529 | 13,907 | 4,359 | -10,548 |
Cost of Revenue | -105,518 | -33,963 | 150,840 | |
Free Cash Flow | -79,016 | -80,332 | -116,554 | -76,327 |
Cash | 135,704 | 81,347 | 186,816 | 220,383 |
Basic Shares | 24,873 | 42,695 | 39,855 | 34,177 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$3.07 |
2024-06-30 | $0.03 |
2024-03-31 | -$0.22 |
2023-12-31 | -$0.22 |
